Therapeutic drug monitoring in inflammatory bowel disease

RDF 

 
This item is provided by the institution :
Hellenic Society of Gastroenterology
Repository :
Annals of Gastroenterology
see item page
in the web site of the repository *
share



Semantic enrichment/homogenization by EKT
Therapeutic drug monitoring in inflammatory bowel disease (EN)

Ben-Horin, Shomron
Seidman, Ernest
Kopylov, Uri

Tumor necrosis factor (TNF)-α inhibitors and thiopurines are among the most important classes of medications utilized in the clinical management of Crohn's disease and ulcerative colitis. A significant proportion of patients loses response to these agents or develops adverse effects during the course of the treatment. Monitoring of drug levels and anti-drug antibodies (for TNF-α inhibitors) and metabolite levels (for thiopurines) can provide valuable insight into the possible etiology of unfavorable outcomes and allow for an appropriate management strategy for these patients. This review summarizes the current knowledge on the clinical implications of therapeutic drug monitoring in inflammatory bowel disease patients treated with TNF-α inhibitors and thiopurines.Keywords Inflammatory bowel disease, Crohn's disease, ulcerative colitis, biologics, thiopurinesAnn Gastroenterol 2014; 27 (4): 304-312 (EN)

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2014-09-30


Hellenic Society of Gastroenterology (EN)

1792-7463
1108-7471
Annals of Gastroenterology; Volume 27, No 4 (2014); 304 (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)